Assessment of combined expression of B7-H3 and B7-H4 as prognostic marker in esophageal cancer patients

Lujun Chen; Quanqin Xie; Zhigang Wang; Liangrong Shi; Changping Wu; Jingting Jiang

doi:10.18632/oncotarget.12628

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Assessment of combined expression of B7-H3 and B7-H4 as prognostic marker in esophageal cancer patients

Lujun Chen, Quanqin Xie, Zhigang Wang, Liangrong Shi, Changping Wu and Jingting Jiang _

PDF | HTML | How to cite

Oncotarget. 2016; 7:77237-77243. https://doi.org/10.18632/oncotarget.12628

Metrics: PDF 2056 views | HTML 2057 views | ?

Abstract

Lujun Chen1,2,5,*, Quanqin Xie1,2,5,*, Zhigang Wang1,2,3,*, Liangrong Shi1,2,4,5, Changping Wu1,2,4,5, Jingting Jiang1,2,5

1Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, China

2Research Center for Cancer Immunotherapy Technology of Jiangsu Province, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, China

3Department of Respiratory Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, China

4Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, China

5Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, China

*These authors have contributed equally to this work

Correspondence to:

Jingting Jiang, email: [email protected]

Keywords: B7-H3, B7-H4, immunohistochemistry, prognosis

Received: April 15, 2016 Accepted: September 14, 2016 Published: October 13, 2016

ABSTRACT

The co-stimulatory ligands of B7-family have been confirmed to play an important role in negatively regulating the T-cell mediated anti-tumor immunity. In addition, these inhibitory molecules are also aberrantly expressed on various human cancers tissues, and significantly associated with cancer progression and patients’ poor prognoses. We have previously reported that B7-H3 and B7-H4 ligands are highly expressed in human esophageal cancer tissues. Herein, we tried to further analyze the value of their combined expression on prognostic prediction for esophageal cancer patients. We found that the combined expression of both B7-H3 and B7-H4 could be used as a valuable risk factor for predicting the prognosis of esophageal cancer patients (P=0.003). Moreover the status of these patients with high expression of both B7-H3 and B7-H4, was positively and significantly associated with the tumor invasion depth (P=0.0414) and TNM stage (P=0.0414). The Cox multivariate proportional hazards regression analysis revealed that the tumor size (P=0.007), the TNM stage (P=0.024) and the status of both B7-H3 and B7-H4 high expression (P=0.011), could be used as an independent risk factor for predicting patients’ postoperative prognosis, respectively. In conclusion, our data indicated that the combined application of B7-H3 and B7-H4 expression can be effectively used as a prognostic marker in esophageal cancer patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12628

Publication Alerts

Research Papers:

Assessment of combined expression of B7-H3 and B7-H4 as prognostic marker in esophageal cancer patients

Abstract